4564 related articles for article (PubMed ID: 3316511)
1. Preparation and antitumor effect of macrophage activating factor (MAF) encapsulated in liposomes bearing a monoclonal anti-human melanoma (A375) antibody.
Watanabe Y; Uchida E; Higuchi M; Imai Y; Osawa T
J Biol Response Mod; 1987 Oct; 6(5):556-68. PubMed ID: 3316511
[TBL] [Abstract][Full Text] [Related]
2. Activation of tumoricidal properties in mouse macrophages by lymphokines encapsulated in liposomes.
Poste G; Kirsh R; Fogler WE; Fidler IJ
Cancer Res; 1979 Mar; 39(3):881-92. PubMed ID: 427777
[TBL] [Abstract][Full Text] [Related]
3. Synergism between lymphokines and muramyl dipeptide encapsulated in liposomes: in situ activation of macrophages and therapy of spontaneous cancer metastases.
Fidler IJ; Schroit AJ
J Immunol; 1984 Jul; 133(1):515-8. PubMed ID: 6373933
[TBL] [Abstract][Full Text] [Related]
4. The role of plasma membrane receptors and the kinetics of macrophage activation by lymphokines encapsulated in liposomes.
Fidler IJ; Raz A; Fogler WE; Hoyer LC; Poste G
Cancer Res; 1981 Feb; 41(2):495-504. PubMed ID: 7004633
[TBL] [Abstract][Full Text] [Related]
5. Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages.
Nakajima H; Fujiwara H; Takai Y; Izumi Y; Sano S; Tsuchida T; Hamaoka T
J Immunol; 1985 Sep; 135(3):2199-205. PubMed ID: 3894520
[TBL] [Abstract][Full Text] [Related]
6. Rat alveolar macrophages are susceptible to activation by free and liposome-encapsulated lymphokines.
Sone S; Poste G; Fidler IJ
J Immunol; 1980 May; 124(5):2197-202. PubMed ID: 7365253
[TBL] [Abstract][Full Text] [Related]
7. Design of liposomes to improve delivery of macrophage-augmenting agents to alveolar macrophages.
Fidler IJ; Raz A; Fogler WE; Kirsh R; Bugelski P; Poste G
Cancer Res; 1980 Dec; 40(12):4460-6. PubMed ID: 7002293
[TBL] [Abstract][Full Text] [Related]
8. Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activators.
Fidler IJ; Barnes Z; Fogler WE; Kirsh R; Bugelski P; Poste G
Cancer Res; 1982 Feb; 42(2):496-501. PubMed ID: 7055801
[TBL] [Abstract][Full Text] [Related]
9. Macrophage activation: synergism between hybridoma MAF and poly(I). Poly(C) delivered by liposomes.
Pidgeon C; Schreiber RD; Schultz RM
J Immunol; 1983 Jul; 131(1):311-4. PubMed ID: 6408176
[TBL] [Abstract][Full Text] [Related]
10. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.
Pastorino F; Brignole C; Marimpietri D; Pagnan G; Morando A; Ribatti D; Semple SC; Gambini C; Allen TM; Ponzoni M
Clin Cancer Res; 2003 Oct; 9(12):4595-605. PubMed ID: 14555535
[TBL] [Abstract][Full Text] [Related]
11. Identification of a unique T cell-derived lymphokine that primes macrophages for tumor cytotoxicity.
Kern DE; Grabstein KH; Okuno K; Schreiber RD; Greenberg PD
J Immunol; 1989 Dec; 143(12):4308-16. PubMed ID: 2687379
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effect of actinomycin D entrapped in liposomes bearing subunits of tumor-specific monoclonal immunoglobulin M antibody.
Hashimoto Y; Sugawara M; Masuko T; Hojo H
Cancer Res; 1983 Nov; 43(11):5328-34. PubMed ID: 6616468
[TBL] [Abstract][Full Text] [Related]
13. Synergistic activation by lymphokines and muramyl dipeptide of tumoricidal properties in rat alveolar macrophages.
Sone S; Fidler IJ
J Immunol; 1980 Dec; 125(6):2454-60. PubMed ID: 7430635
[TBL] [Abstract][Full Text] [Related]
14. Macrophage tumoricidal activity as a possible antitumor mechanism associated with the local injection of allogeneic spleen cells into rats.
Kawase I; Komuta K; Namba M; Yokota S; Ogura T; Kishimoto S
Cancer Res; 1986 Mar; 46(3):1047-54. PubMed ID: 3510719
[TBL] [Abstract][Full Text] [Related]
15. Lymphocyte supernatant-induced human monocyte tumoricidal activity: dependence on the presence of gamma-interferon.
Sadlik JR; Hoyer M; Leyko MA; Horvat R; Parmely M; Whitacre C; Zwilling B; Rinehart JJ
Cancer Res; 1985 May; 45(5):1940-5. PubMed ID: 3921233
[TBL] [Abstract][Full Text] [Related]
16. Production of macrophage-activating factor by T lymphocyte clones and correlation with other lymphokine activities.
Kelso A; Glasebrook AL; Kanagawa O; Brunner KT
J Immunol; 1982 Aug; 129(2):550-6. PubMed ID: 7045227
[TBL] [Abstract][Full Text] [Related]
17. Sterically stabilized anti-G(M3), anti-Le(x) immunoliposomes: targeting to B16BL6, HRT-18 cancer cells.
Nam SM; Kim HS; Ahn WS; Park YS
Oncol Res; 1999; 11(1):9-16. PubMed ID: 10451027
[TBL] [Abstract][Full Text] [Related]
18. Activation of murine macrophages. I. Different pattern of activation by poly I:C than by lymphokine or LPS.
Taramelli D; Varesio L
J Immunol; 1981 Jul; 127(1):58-63. PubMed ID: 6787132
[TBL] [Abstract][Full Text] [Related]
19. Phenotypic characterization of human T lymphocyte populations producing macrophage-activating factor (MAF) lymphokines.
Biondi A; Roach JA; Schlossman SF; Todd RF
J Immunol; 1984 Jul; 133(1):281-5. PubMed ID: 6373929
[TBL] [Abstract][Full Text] [Related]
20. Identification and characterization of a human T cell line-derived lymphokine with MAF-like activity distinct from interferon-gamma.
Lee JC; Rebar L; Young P; Ruscetti FW; Hanna N; Poste G
J Immunol; 1986 Feb; 136(4):1322-8. PubMed ID: 3003193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]